Intercell: GSK takes stake
Vienna – Austrian vaccine specialist Intercell and GlaxoSmithKline Biologicals SA (GSK) have formed a strategic alliance to commercialise needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine for travelers’ diarrhea (TD) and an investigational single-application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK’s portfolio. GSK will make an up-front cash contribution of EUR33.6m in addition to an equity investment of up to EUR84m through a staggered shareholding purchase option of up to 5% in Intercell. Included in the agreement are Intercell’s investigational TD vaccine, which is currently in Phase III trials. The pandemic influenza vaccine is in Phase II trials.